References

EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies

10.1136/annrheumdis-2019-216114 · 2020 · External reference

Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)

10.1007/s10067-022-06391-w · 2023 · External reference

Cryoglobulinemic vasculitis in primary Sjögren’s syndrome: clinical presentation, association with lymphoma and comparison with hepatitis C-related disease

10.1016/j.semarthrit.2020.07.013 · 2020 · External reference

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

10.1016/s2352-3026(17)30078-9 · 2017 · External reference

Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia

10.2217/fon-2017-0574 · 2018 · External reference

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

10.1093/annonc/mdw685 · 2017 · External reference

Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remission

10.1093/rheumatology/keaf324 · 2025 · External reference

Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission

10.3389/fmed.2025.1583401 · 2025 · External reference